

SUPPLEMENTAL DATA

***STAT3* mutations identified in human hematological neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model.**

Lucile Couronné,^{1,2,3} Laurianne Scourzic,^{1,2,3} Camilla Pilati,^{4,5} Véronique Della Valle,^{1,2,3} Yannis Duffourd,³ Eric Solary,^{2,3,6} William Vainchenker,^{2,3,6} Jean-Philippe Merlio,⁷ Marie Beylot-Barry,⁷ Frederik Damm,^{1,2,3} Marc-Henri Stern,⁸ Philippe Gaulard,^{9,10} Laurence Lamant,¹¹ Eric Delabesse,¹¹ Hélène Merle-Beral,¹² Florence Nguyen-Khac,¹² Michaëla Fontenay,¹³ Hervé Tilly,¹⁴ Christian Bastard,¹⁴ Jessica Zucman-Rossi,^{4,5} Olivier A. Bernard,^{1,2,3} and Thomas Mercher.^{1,3,15}

¹ INSERM, U985, Villejuif, France

² Université Paris-Sud, Orsay, France

³ Institut Gustave Roussy, Villejuif, France

⁴ INSERM, UMR-674, Génomique fonctionnelle des tumeurs solides, IUH, Paris, France

⁵ Université Paris Descartes, Labex Immuno-oncology, Sorbonne Paris Cité, Faculté de Médecine, Paris, France

⁶ INSERM, U1009, Villejuif, France

⁷ CRB Tumorothèque, CHU de Bordeaux, EA 2406, Université Bordeaux, Bordeaux, France

⁸ INSERM, U830, Institut Curie, Paris, France

⁹ Inserm U955, Université Paris-Est-Créteil (UPEC), Créteil, France

¹⁰ Département de pathologie, AP-HP, Groupe Henri-Mondor Albert-Chenevier, Créteil, France

¹¹ Centre de Recherche en Cancérologie de Toulouse, INSERM UMR1037, CNRS ERL 5294, CHU Purpan, Université Paul Sabatier, Toulouse, France

¹² Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, APHP, Université Pierre et Marie Curie-Paris 6, INSERM U872, Paris, France

¹³ Assistance Publique-Hôpitaux de Paris, Service d'Hématologie Biologique, Groupe Hospitalier Broca-Cochin-Hôtel-Dieu; Institut Cochin, Département d'Immuno-Hématologie, INSERM U1016, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 8104, Université Paris Descartes, Faculté de Médecine Paris Descartes, France

¹⁴ INSERM, U918, Université de Rouen, Centre Henri Becquerel, Rouen, France

¹⁵ Université Paris Diderot, Paris, France

Supplemental data legends

Figure S1: Percentages of GFP-positive cells at different time-points after transduction.

A. Transduction efficiencies in the bone marrow cells right after the second spinfection and just before the injection into the primary recipients.

B. Representative percentages of GFP in the blood leukocytes of primary recipients at 1 month post-transplantation.

C. Percentage of GFP-positive cells in the bone marrow and spleen cells from three independent STAT3Y640F primary recipients at the time of transplantation into secondary recipients.

Figure S2: *STAT3* mutations in patients, proliferation assays and hematological follow-up of *in vivo* murine models.

A. *STAT3* sequences in tumor samples.

Vertical arrows indicate the sequence variations. Horizontal arrows indicate the origin of the indel mutations.

B. Proliferation assay of transduced murine BAF3 cells with empty, wild-type (WT), *STAT3* or *STAT3 Y640F* MSCV retroviruses in presence of IL3, IL4 or FLT3 ligand, as compared to a condition without cytokines (control).

C. White blood cells (WBC) count, hemoglobin level, platelets count and percentage of GFP-positive cells follow up of the individual 395 (*STAT3 Y640F* mice with thrombocytosis disease). The x-axis values represent the number of months after bone marrow transplantation.

Table S1: List of primers used for *STAT3* PCR and sequencing

Table S2: Antibodies combinations used for flow cytometry

Table S3: Clinical data of *STAT3* mutated patients

Figure S1




Figure S2




Table S1: List of primers used for *STAT3* PCR and sequencing

<i>STAT3</i> exon3F	GAATGGGTTATAGCATCAGG
<i>STAT3</i> exon3R	CTCAGGTAATGATGCTCACG
<i>STAT3</i> exon6F	TTTTCTGTTCCCAAGGAAAT
<i>STAT3</i> exon6R	CCCGCCTTAAGATCTAAACAGA
<i>STAT3</i> exon17F	GACCCACTCCTTGCCAGTT
<i>STAT3</i> exon17R	CAGTAGACATGGCCCAAATG
<i>STAT3</i> exon20F	TGTAACCAAGTCCCCTGCTC
<i>STAT3</i> exon20R	CAGGGGGCAGTAGGTGCT
<i>STAT3</i> exon21F	AGTCTTTTCCCCTTCGAGGA
<i>STAT3</i> exon21R	CAAGGATCCCAAATTTCCA

Table S2: Antibodies combinations used for flow cytometry

Antibody	Clone	Fluorochrome	Source
CD11b (Mac)	M1/70	PE	eBioscience
Ly-6G (Gr-1)	RB6-8C5	PE-Cy7	eBioscience
CD41	MWReg30	APC	eBioscience
CD42b (GPIb α)	Xia.G5	PE	Emfret Analytics
CD71	RI7 217.1.4	PE	eBioscience
Ter119	TER-119	APC	eBioscience

PE: phycoerythrin, APC : allophycocyanin, PE-Cy7: phycoerythrin-cyanine 7

Table S3: Clinical data of *STAT3* mutated patients

PTCL, NOS Y640F	<p>60-year-old man Diagnosed in 2004, with a PTCL, NOS stage IV (bone marrow, spleen and liver involvement) CD8+ CD3-CD5-CD4- Normal karyotype CD4 lymphopenia and paraneoplastic dysautonomia syndrom Therapy: 4 ACVBP, 2 MTX, 4 Holoxan/Vp16 and 2 Aracytine cycles Currently in complete remission (8,5 years of follow up)</p>
Gamma-delta T lymphoma Y657ins	<p>38-year-old man Common variable immunodeficiency (CVID) with hypogammaglobulinemia, B and T-cell lymphopenia diagnosed in 1995 Diagnosed in May 1998 with a circulating CD3+ gamma/delta T-cell clone that may correspond with the leukemic phase of a gamma/delta T-cell lymphoma Therapy: methotrexate per os (during 6 months, stopped because of digestive intolerance) JC virus-positive progressive multifocal leukoencephalopathy (PML) in January 2000 Death on April 2000 (PML in the context of CVID and gamma/delta T-cell lymphoma)</p>
DLBCL E616del #1	<p>82-year-old man Diagnosed in November 2008 with a DLBCL stage II (cervical lymph nodes) GC subtype CD10+ Complex karyotype (hyperdiploidy) Autoimmune hepatitis Therapy: 4 R-miniCHOP cycles (did not get the two last ones because of a E. Coli septicemia) In complete remission in August 2009 (9 months of follow-up) No follow up since August 2009</p>
DLBCL E616del #2	<p>56-year-old man Diagnosed in March 2006 with a DLBCL stage III (cervical lymph nodes, spleen involvement) GC subtype Therapy:4 R-ACVBP, 2 high dose Methotrexate cycles and an high dose conditioning regimen (BEAM) with autologous bone marrow transplantation In complete remission in July 2012 (6 years of follow up)</p>
cALCL D661ins	<p>72-year-old man Stage T1bN0M0 Relapse 6 months after remission (Global survival: 15 months)</p>
cALCL D661Y	<p>82-year-old woman Stage T3cN0M0 No remission (Global survival: 6 months)</p>